Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone E Dekker

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Blood Advances|May 7, 2025
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS InvolvementIbrahim N Muhsen, Gregory W Roloff, Rawan G Faramand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood Advances|August 2, 2024
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALLIbrahim Aldoss, Gregory W Roloff, Rawan Faramand, et al.
Bone Marrow Transplantation|August 23, 2025
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemiaTimothy E O'Connor, Chenyu Lin, Gregory W Roloff, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Blood Advances|May 7, 2025
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS InvolvementIbrahim N Muhsen, Gregory W Roloff, Rawan G Faramand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood Advances|August 2, 2024
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALLIbrahim Aldoss, Gregory W Roloff, Rawan Faramand, et al.
Bone Marrow Transplantation|August 23, 2025
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemiaTimothy E O'Connor, Chenyu Lin, Gregory W Roloff, et al.
Pageof 5